¼¼°èÀÇ Àç»ý ÀǾàǰ ½ÃÀå ¿¹Ãø(2025-2030³â)
Global Regenerative Drugs Market - Forecasts fom 2025 to 2030
»óǰÄÚµå : 1800149
¸®¼­Ä¡»ç : Knowledge Sourcing Intelligence
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 144 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,950 £Ü 5,567,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,550 £Ü 6,413,000
PDF (Multiple User License) help
PDF º¸°í¼­¸¦ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,796,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Àç»ý ÀǾàǰ ½ÃÀåÀº CAGR 14.86%¸¦ ³ªÅ¸³» 145¾ï 4,000¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 290¾ï 6,300¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Àç»ý ÀǾàǰÀº °Ç°­ °ü¸®ÀÇ Çõ½ÅÀûÀÎ Á¢±Ù¹ýÀÌ¸ç ¼Õ»óµÈ Á¶Á÷°ú ±â°üÀ» º¹±¸, ´ëü ¹× Àç»ýÇÏ¿© Á¤»óÀûÀÎ ½Åü ±â´ÉÀ» ȸº¹½ÃŰ´Â µ¥ ÁßÁ¡À» µÓ´Ï´Ù. ÀÌ·¯ÇÑ ÀǾàǰÀº °Ç°­ÇÑ ¼¼Æ÷³ª Á¶Á÷À» Áúȯ ºÎÀ§³ª ¼Õ»ó ºÎÀ§¿¡ Àü´ÞÇÏ´Â Àç»ýÀ̳ª ¼Õ»ó ºÎÀ§ÀÇ ´ë¿ëÀ¸·Î ±âÁõÀÚÀÇ °Ç°­ÇÑ ¼¼Æ÷, Á¶Á÷, Àå±â¸¦ »ç¿ëÇϴ ġȯ µîÀÇ °úÁ¤À» ÀÌ¿ëÇÏ¿© ÀÚ¿¬ÀûÀ¸·Î ȸº¹ÇÒ ¼ö ¾ø´Â Á¶Á÷À» Ä¡À¯ÇÔÀ¸·Î½á ȸÃáÀ» ÃËÁøÇÕ´Ï´Ù. Àç»ý ÀÇÇÐÀÇ Áß¿äÇÑ ¹ßÀüÀº ȯÀÚ ÀÚ½ÅÀÇ ¼¼Æ÷¸¦ »ç¿ëÇÏ¿© ½ÇÇè½Ç ³»¿¡¼­ Àå±â¸¦ ¹è¾çÇϰí, ÀÌ½Ä °ÅºÎ ¹ÝÀÀÀÇ À§ÇèÀ» ÁÙÀ̰í, Àå±â ºÎÁ· ¹®Á¦¸¦ ÇØ°áÇÒ ¼ö ÀÖ´Ù´Â °ÍÀÔ´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ ºÐ¾ß´Â ´Ù¾çÇÑ ÀÇ·á ºÐ¾ß¿¡¼­ Ä¡·á¿¡ Çõ¸íÀ» °¡Á®¿Ã °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­´Â À¯Çüº°, Àç·áº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°·Î ±¸ºÐµË´Ï´Ù. À¯Çüº°·Î´Â ÇÕ¼º¾à, »ý¹°ÇÐÀû À¯·¡¾à, À¯ÀüÀÚÀ¯·¡¾àÀÌ ÀÖ¾î Á¶Á÷¼ö¸®¡¤Àç»ý¿¡ ´ëÇÑ ´Ù¾çÇÑ Á¢±Ù¹ýÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¿¡ »ç¿ëµÇ´Â Àç·á´Â »ýºÐÇØ¼º ÇÕ¼º ÁßÇÕü, ½ºÄ³Æúµå, ÇÏÀ̵å·Î°Ö, Äݶó°Õ, À¯ÀüÀÚ ÀçÁ¶ÇÕ Àç·á, ¼¶À¯¾Æ¼¼Æ÷ µîÀ» Æ÷ÇÔÇϸç, °¢°¢Àº ƯÁ¤ Àç»ý ¿ä±¸¿¡ ¸Â°Ô Á¶Á¤µË´Ï´Ù. ¿ëµµ´Â ½ÉÀåÇ÷°ü, Á¾¾ç, ÇǺÎ, ±Ù°ñ°Ý°è, »óó Ä¡À¯, ¾È°ú, ½Å°æ µîÀÇ Áß¿äÇÑ ºÐ¾ß ¹× Àç»ýÁ¦ÀÇ ±¤¹üÀ§ÇÑ Ä¡·á °¡´É¼ºÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÃÖÁ¾ »ç¿ëÀÚ´Â º´¿ø, »ý¹° ÀÇÇÐ ¿¬±¸¼Ò ¹× ¿¬±¸¼¾Å͸¦ Æ÷ÇÔÇÏ¿© ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ Çõ½Å°ú ÀÀ¿ëÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù.

Áö¿ªÀûÀ¸·Î ½ÃÀåÀº ºÏ¹Ì, ³²¹Ì, À¯·´, Áßµ¿, ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ³ª´¹´Ï´Ù. À¯·´, ƯÈ÷ µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹Àº Àç»ý ÀǾàǰÀÇ ÁÖ¿ä ±âÁö ¿ªÇÒÀ» Çϸç, ¼¼Æ÷ ±â¹Ý Ä¡·á¿¡ ÁßÁ¡À» µÐ °­·ÂÇÑ »ó¾÷ ºÎ¹®ÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº ȯÀÚÀÇ ÀÚ°¡¼¼Æ÷³ª Ç÷¿¬ÀÌ ¾ø´Â ±âÁõÀڷκÎÅÍÀÇ µ¿Á¾ ¼¼Æ÷¸¦ ÀÌ¿ëÇÏ´Â °æ¿ì°¡ ¸¹À¸¸ç, ´Ù¾çÇÑ ÀÓ»ó ¿ä±¸¿¡ ´ëÀÀÇϰí, ¸ÂÃãÇü ÀǷḦ ÁøÇàÇϰí ÀÖ½À´Ï´Ù.

Àç»ý ÀǾàǰ ½ÃÀåÀº °æÀïÀÌ ½ÉÇϰí Baxter International, Stryker Corporation, Medtronic plc, CryoLife, Inc., Organogenesis, Inc.(Advanced BioHealing) µî ÁÖ¿ä ±â¾÷ÀÌ ¾÷°è¸¦ ¼±µµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº ¿¬±¸°³¹ßÀ» ÅëÇØ Çõ½ÅÀ» ÃßÁøÇÏ°í ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇÑ ½Å±Ô Ä¡·á¹ý°ú È®Àå °¡´ÉÇÑ ¼Ö·ç¼Ç¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â °ÍÀº Àç»ý ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡ÇÏ°í ¸¸¼º ¹× ÅðÇ༺ Áúȯ¿¡ ´ëÇÑ È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ Çʿ伺ÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù.

°á·ÐÀûÀ¸·Î, Àç»ý ÀǾàǰ ½ÃÀåÀº ¼¼Æ÷ ±â¹Ý Ä¡·á¹ý°ú Àå±â Àç»ý ±â¼úÀÇ Áøº¸¿¡ °ßÀÎµÇ¾î »ó´çÇÑ È®´ë°¡ ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­ÀÇ Á¸Àç°¨ÀÇ Èû°ú ¼¼°èÀÇ º¸±ÞÀÇ ³ô¾ÆÁü°ú ´õºÒ¾î, ÀÇ·á ºÐ¾ß Àüü¿¡ÀÇ Æø³ÐÀº ÀÀ¿ëÀÌ, ÇコÄɾ º¯ÇõÇÒ °¡´É¼ºÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷ÀÌ Çõ½ÅÀ» °è¼ÓÇÏ°í Æ÷Æ®Æú¸®¿À¸¦ È®´ëÇÏ´Â µ¿¾È Àç»ý ÀǾàǰ´Â ¾ð¸ÞÆ® ÀÇ·á ¿ä±¸¿¡ ´ëÇÑ ´ëÀÀ°ú ȯÀÚ °á°ú °³¼±¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÁÖ¿ä ÀÌÁ¡

¾î¶² ¿ëµµ·Î »ç¿ëµË´Ï±î?

¾÷°è ¹× ½ÃÀå ÀλçÀÌÆ®, »ç¾÷ ±âȸ Æò°¡, Á¦Ç° ¼ö¿ä ¿¹Ãø, ½ÃÀå ÁøÃâ Àü·«, Áö¸®Àû È®´ë, ¼³ºñ ÅõÀÚ °áÁ¤, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°ú ¿µÇâ, ½ÅÁ¦Ç° °³¹ß, °æÀïÀÇ ¿µÇâ

Á¶»ç ¹üÀ§

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå ÇöȲ

Á¦3Àå ºñÁî´Ï½º »óȲ

Á¦4Àå ±â¼ú Àü¸Á

Á¦5Àå ¼¼°èÀÇ Àç»ý ÀǾàǰ ½ÃÀå : ±â¼úº°

Á¦6Àå ¼¼°èÀÇ Àç»ý ÀǾàǰ ½ÃÀå : ¼ÒÀ纰

Á¦7Àå ¼¼°èÀÇ Àç»ý ÀǾàǰ ½ÃÀå : ¿ëµµº°

Á¦8Àå ¼¼°èÀÇ Àç»ý ÀǾàǰ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦9Àå ¼¼°èÀÇ Àç»ý ÀǾàǰ ½ÃÀå : Áö¿ªº°

Á¦10Àå °æÀï ȯ°æ°ú ºÐ¼®

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦12Àå ºÎ·Ï

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Regenerative Drugs Market is expected to grow from USD 14.540 billion to USD 29.063 billion in 2030, at a CAGR of 14.86%.

Regenerative drugs represent a transformative approach in healthcare, focusing on repairing, replacing, or regenerating damaged tissues and organs to restore normal bodily functions. These medicines facilitate rejuvenation by healing tissues that cannot naturally recover, using processes such as regeneration, where healthy cells or tissues are delivered to diseased or damaged areas, or replacement, where healthy cells, tissues, or organs from donors are used to substitute damaged ones. A significant advancement in regenerative medicine is the potential to grow organs in laboratory settings using a patient's own cells, reducing the risk of transplant rejection and addressing organ shortage challenges. This innovative field holds promise for revolutionizing treatment across various medical domains.

The global regenerative drugs market is segmented by type, materials, application, end-users, and geography. By type, the market includes synthetic, biologically derived, and genetically derived drugs, reflecting diverse approaches to tissue repair and regeneration. Materials used in these therapies encompass biodegradable synthetic polymers, scaffolds, hydrogel and collagen, transgenic materials, and fibroblasts, each tailored to specific regenerative needs. Applications span critical areas such as cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others, highlighting the broad therapeutic potential of regenerative drugs. End-users include hospitals, biomedical laboratories, and research centers, which drive innovation and application of these therapies.

Geographically, the market is divided into North America, South America, Europe, the Middle East, and the Asia-Pacific region. Europe, particularly Germany, France, and the UK, serves as a major hub for regenerative medicine, with a strong commercial sector focused on cell-based therapies. These therapies often utilize autologous cells from the patient or allogeneic cells from unrelated donors, catering to diverse clinical needs and advancing personalized medicine.

The regenerative drugs market is highly competitive, with key players such as Baxter International, Stryker Corporation, Medtronic plc, CryoLife, Inc., and Organogenesis, Inc. (Advanced BioHealing) leading the industry. These companies are driving innovation through research and development, focusing on novel therapies and scalable solutions to meet growing demand. The market's growth is fueled by increasing investment in regenerative technologies and a rising need for effective treatments for chronic and degenerative diseases.

In conclusion, the regenerative drugs market is poised for significant expansion, driven by advancements in cell-based therapies and organ regeneration techniques. Its broad applications across medical fields, coupled with a strong presence in Europe and growing global adoption, underscore its potential to transform healthcare. As key players continue to innovate and expand their portfolios, regenerative medicines will play a pivotal role in addressing unmet medical needs and improving patient outcomes.

Key Benefits of this Report:

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Segmentation:

By Technology

By Materials

By Applications

By End-Users

By Geography

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

3. BUSINESS LANDSCAPE

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL REGENERATIVE DRUGS MARKET BY TECHNOLOGY

6. GLOBAL REGENERATIVE DRUGS MARKET BY MATERIALS

7. GLOBAL REGENERATIVE DRUGS MARKET BY APPLICATIONS

8. GLOBAL REGENERATIVE DRUGS MARKET BY END-USERS

9. GLOBAL REGENERATIVE DRUGS MARKET BY GEOGRAPHY

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

11. COMPANY PROFILES

12. APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â